SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-292007
Filing Date
2022-11-23
Accepted
2022-11-23 16:03:02
Documents
12
Period of Report
2022-11-18
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d169360d8k.htm   iXBRL 8-K 25792
  Complete submission text file 0001193125-22-292007.txt   151093

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ayla-20221118.xsd EX-101.SCH 2863
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ayla-20221118_lab.xml EX-101.LAB 18670
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ayla-20221118_pre.xml EX-101.PRE 11692
6 EXTRACTED XBRL INSTANCE DOCUMENT d169360d8k_htm.xml XML 3456
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39279 | Film No.: 221416304
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences